Chidozie Ugwumba Sells 12,665 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 12,665 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $5.32, for a total transaction of $67,377.80. Following the transaction, the insider directly owned 605,159 shares of the company’s stock, valued at $3,219,445.88. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total value of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total value of $127,653.45.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The shares were sold at an average price of $5.50, for a total value of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total value of $19,457.55.

Clene Stock Performance

Shares of NASDAQ CLNN traded down $0.11 during midday trading on Friday, hitting $5.31. 60,597 shares of the company’s stock traded hands, compared to its average volume of 132,786. The firm has a fifty day moving average of $6.82 and a 200 day moving average of $6.48. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The stock has a market capitalization of $57.61 million, a price-to-earnings ratio of -1.57 and a beta of 0.87.

Clene (NASDAQ:CLNN) last announced its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. On average, equities analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current year.

Hedge Funds Weigh In On Clene

Several hedge funds have recently bought and sold shares of CLNN. Jones Financial Companies Lllp bought a new stake in shares of Clene during the third quarter worth $29,000. Jane Street Group LLC bought a new position in shares of Clene in the second quarter worth about $47,000. Lunt Capital Management Inc. increased its stake in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares during the period. Finally, Scoggin Management LP lifted its holdings in Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares in the last quarter. Institutional investors own 23.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CLNN. Benchmark reaffirmed a “buy” rating on shares of Clene in a report on Thursday, December 4th. UBS Group reaffirmed a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Finally, D. Boral Capital reiterated a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Clene currently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).